Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cumberland Pharmaceuticals

4.99
-1.3800-21.66%
Post-market: 4.77-0.2200-4.41%17:56 EDT
Volume:205.21K
Turnover:1.13M
Market Cap:70.07M
PE:-10.83
High:6.39
Open:6.39
Low:4.75
Close:6.37
Loading ...

Cumberland Pharmaceuticals Gets FDA's Supplemental NDA Approval for Acetadote; Shares Soar After Hours

MT Newswires Live
·
10 Dec 2024

Cumberland Pharma Shares Rise 56% After FDA Approves Liver Drug Acetadote

Dow Jones
·
10 Dec 2024

BRIEF-FDA Approves Acetadote® SNDA

Reuters
·
10 Dec 2024

Cumberland announces FDA approves sNDA for Acetadote product

TIPRANKS
·
10 Dec 2024

FDA Approves Acetadote® Snda

THOMSON REUTERS
·
10 Dec 2024

Cumberland Pharmaceuticals Inc - New Dosing Regimen Simplifies Acetadote Administration

THOMSON REUTERS
·
10 Dec 2024

FDA APPROVES ACETADOTE® sNDA

PR Newswire
·
10 Dec 2024

Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023)

Simply Wall St.
·
10 Nov 2024

Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ...

GuruFocus.com
·
09 Nov 2024

Cumberland Q3 Adj $(0.02) Down From $0.02 YoY, Sales $9.09M Down From $10.09M YoY

Benzinga
·
08 Nov 2024

Cumberland: Q3 Earnings Snapshot

Associated Press Finance
·
08 Nov 2024

Cumberland Pharmaceuticals Q3 Adjusted EPS USD -0.02

THOMSON REUTERS
·
08 Nov 2024

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

PR Newswire
·
08 Nov 2024

Cumberland receives FDA orphan, RPDD designation for Ifetroban

TIPRANKS
·
07 Nov 2024

BRIEF-Cumberland Pharmaceuticals Receives FDA Orphan Drug And Rare Pediatric Disease Designations For New Treatment Of Duchenne Muscular Dystrophy

Reuters
·
07 Nov 2024

Cumberland Pharmaceuticals Receives FDA Orphan Drug and Rare Pediatric Disease Designations for New Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
07 Nov 2024